Illumina Jun 7, 2026 Illumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch - Yahoo Finance
Novo Nordisk Jun 7, 2026 Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026 - PR Newswire
Fritsch GmbH Jun 7, 2026 Crushing and Pulverizing Equipment Market Forecast Points Higher Toward 2035, Driven by Infrastructure and Critical Mineral Demand - News and Statistics - IndexBox
FierceBiotech Jun 7, 2026 ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
Roche Media Jun 7, 2026 ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect - Fierce Biotech
MIURA CO.,LTD. Jun 6, 2026 Miura Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:MIURF) 2026-06-06 - Seeking Alpha
10x Genomics News Jun 6, 2026 10x Genomics (TXG) Is Up 9.7% After Momentum Rally Despite Weak Fundamentals - What's Changed - simplywall.st
FierceBiotech Jun 6, 2026 ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes
Cell Jun 6, 2026 Deep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation
FierceBiotech Jun 6, 2026 ADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy
Endpoints News Jun 6, 2026 #ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year
FierceBiotech Jun 6, 2026 ‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs